Inotersen sodium

N/A

Report date: 2022/01/29 15:33:47
NMEFirst In Class

Base Information

Drug NameInotersen sodium
Drug Alias Name伊诺特生Human transthyretin antisense oligonucleotideIONIS-TTRRxISIS-GSK1RxInotersenum +[9] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionRNA interferenceTransthyretin inhibitors
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisAmyloidosisAmyloid Neuropathies, Familial +[4] 
Global Approved IndicationsTransthyretin amyloidosisAmyloidosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2018/07/05
Country/TerritoryUnited StatesPortugalNew Zealand +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIonis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesPtc Therapeutics IncAstrazeneca PlcAkcea Therapeutics Ireland Ltd
Inactive CompaniesThe Brigham and Women's HospitalIonis Pharmaceuticals IncAkcea Therapeutics Inc
Active IndicationsTransthyretin amyloidosisAmyloidosis
Inactive IndicationsAmyloid Neuropathies, FamilialAdenomatous Polyposis Coli

Other Information

ATC CodeN07XX15
Related LinksN/A